EAU 2025 | 100% Specificity Achieved! Qilu Hospital of Shandong University’s “Non-Biopsy” Prostate Cancer Study Presented as Oral Report

EAU 2025 | 100% Specificity Achieved! Qilu Hospital of Shandong University’s “Non-Biopsy” Prostate Cancer Study Presented as Oral Report

Prostate biopsy remains the gold standard for diagnosing prostate cancer, but it carries risks such as infection, bleeding, and urinary obstruction. As a result, growing research interest has focused on developing “non-biopsy” diagnostic strategies. At the 2025 Annual Meeting of the European Association of Urology (EAU25), a study led by Professor Shouzhen Chen and Professor Benkang Shi from Qilu Hospital of Shandong University was selected for oral presentation. The study demonstrated that combining PSMA PET/CT, multiparametric MRI (PI-RADS score), and blood biomarkers—PHI and PSAD—can reduce the prostate cancer missed diagnosis rate to zero.
Professor Ying Fan Wins SGBCC Best Poster Award for Real-World Study on HER2-Positive Breast Cancer in the Neoadjuvant Setting

Professor Ying Fan Wins SGBCC Best Poster Award for Real-World Study on HER2-Positive Breast Cancer in the Neoadjuvant Setting

The 19th St. Gallen Breast Cancer Conference (SGBCC), held in Vienna from March 12 to 15, 2025, remains one of the most influential global platforms in early breast cancer care. Among seven studies awarded the prestigious Best Poster Award, four came from China, including a multi-center real-world study led by Professor Ying Fan from the Cancer Hospital Chinese Academy of Medical Sciences. Her research focused on treatment-insensitive HER2-positive breast cancer patients undergoing neoadjuvant therapy. Oncology Frontier spoke with Professor Fan to learn more about the study’s results, and broader implications.
EAU 2025 | CUHK’s Peter Chiu and Team Highlight Advances in Precision Biopsy and Standardized Treatment for Prostate Cancer

EAU 2025 | CUHK’s Peter Chiu and Team Highlight Advances in Precision Biopsy and Standardized Treatment for Prostate Cancer

Prostate cancer remains one of the most prevalent malignancies threatening men’s health worldwide. A major research focus today lies in developing accurate screening and diagnostic strategies that minimize the invasiveness and psychological burden of biopsy procedures. Landmark studies like SMART and PRECISION aim to address these challenges. At the 2025 European Association of Urology (EAU) Annual meeting, Professor Chiu Ka Fung Peter from the Department of Urology at The Chinese University of Hong Kong presented the latest findings from the SMART study. Following his presentation, Professor Chiu spoke with UroStream to share key updates in prostate cancer diagnostics and care.